人 PLCG1 抗体对
01AB01801
Phospholipase C gamma 1 (PLCG1) is a cytosolic enzyme that plays a pivotal role in intracellular signaling by coupling receptor tyrosine kinases, such as EGFR and PDGFR, to downstream cellular processes. Upon activation by phosphorylation, PLCG1 hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG). These messengers trigger calcium release and protein kinase C activation, regulating cell proliferation, survival, migration, and cytoskeletal remodeling. Structurally, PLCG1 contains SH2 and SH3 domains that mediate its recruitment and activation. Clinically, PLCG1 is a major oncogenic driver; recurrent activating mutations and gene amplifications lead to constitutive signaling in various malignancies. Its overexpression is frequently associated with increased tumor invasiveness and poor prognosis, particularly in lower-grade gliomas.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- PLCG1
- 基因别名
- PLC1
- 蛋白别名
- phospholipase C gamma 1; PLCG1
- UniProt
- P19174
- 物种
- Human
产品详情
- 靶点名称
- PLCG1
- 蛋白名称
- phospholipase C gamma 1
- 蛋白别名
- 1-phosphatidylinositol 4; 5-bisphosphate phosphodiesterase gamma-1; PLC-148; Phosphoinositide phospholipase C-gamma-1; Phospholipase C-II; PLC-II; Phospholipase C-gamma-1; PLC-gamma-1
- 靶点基因名
- PLCG1
- 基因别名
- PLC1
- UniProt
- P19174
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Phospholipase C gamma 1 (PLCG1) is a cytosolic enzyme that plays a pivotal role in intracellular signaling by coupling receptor tyrosine kinases, such as EGFR and PDGFR, to downstream cellular processes. Upon activation by phosphorylation, PLCG1 hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG). These messengers trigger calcium release and protein kinase C activation, regulating cell proliferation, survival, migration, and cytoskeletal remodeling. Structurally, PLCG1 contains SH2 and SH3 domains that mediate its recruitment and activation. Clinically, PLCG1 is a major oncogenic driver; recurrent activating mutations and gene amplifications lead to constitutive signaling in various malignancies. Its overexpression is frequently associated with increased tumor invasiveness and poor prognosis, particularly in lower-grade gliomas.